Tennessee Governor Bill Lee joined partners to present the nation's first-ever license specifically for a commercial fusion machine to Type One Energy at the Bull Run Site.
Helion became the first company to secure Washington State DOH licenses for a fusion power plant, moving closer to commercial operation.
Helion received the licenses from Washington State's Department of Health needed to build and operate its 50MW fusion plant in Malaga, WA — the first US (and per the company, world-first) fusion firm to clear the full regulatory path for a power plant. It clears a key gate toward construction of a plant slated to supply Microsoft.
CFS submitted an interconnection request to PJM Interconnection (the largest U.S. wholesale electricity market) to connect its first ARC fusion power plant in Chesterfield County, Virginia, targeting power delivery in the early 2030s. It is the first fusion company ever to enter a grid-interconnection queue — a concrete, regulated step from R&D toward commercial generation.
The European Commission granted Ilumira, SHINE's non-carrier-added lutetium-177 chloride, a centralised marketing authorisation valid throughout the European Union on 26 March 2026, per the EMA's own EPAR record (reference EMA/48983/2026, first published 1 April 2026). Ilumira is a radiolabelling agent — never given directly to a patient — used to label other medicines that carry Lu-177 to tumour sites, with presented data covering neuroendocrine tumours and prostate cancer. The clearance is the regulatory prerequisite for selling Lu-177 into the EU and opens one of the world's largest radioligand-therapy markets to a US-based supplier. DATE PRECISION: SHINE did not announce this until 29 May 2026, 64 days after the authorisation date. This record is dated to the regulator's decision, not the company's announcement.